ARCHIVES

Risk Assessment Key In Long-Term Treatment

This article is from The Cancer Letter archive.

Vol. 31 No. 8 | August 29, 2008

Download PDF Visit The Full Archive

Related Articles

Letter to the Editor: A Victory for Research, But Real Work Is Ahead

November 26, 1999

In Brief: Some Cancer Centers Funded At “Recommended” Levels For Fiscal 1981, But There Was A Catch

October 30, 1981

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

NCI CTEP Approved Trials For the Month of April

April 25, 2014

(8-page issue).

January 31, 2003

In Brief: Washington University, Barnes-Jewish to Combine Cancer Program In New Center

December 3, 1999